Abstract
The application discloses a specific ACKR2 modulator for use in the treatment of a proliferative disease or disorder in a subject and/or for use in improving the response of a subject to anticancer immunotherapy. The application further discloses pharmaceutical compositions comprising such a specific ACKR2 modulator and one or more immune checkpoint inhibitors
Original language | English |
---|---|
Patent number | WO 2021/009251 |
IPC | A61K39/395; A61K48/00; A61P35/00; C07K16/28; C12N15/113 |
Priority date | 15/07/19 |
Filing date | 15/07/20 |
Publication status | Published - 21 Jan 2021 |